Literature DB >> 10532547

Comparison of chimeric acid and non-chimeric tolerance using posttransplant total lymphoid irradiation: cytokine expression and chronic rejection.

K Hayamizu1, F Lan, P Huie, R K Sibley, S Strober.   

Abstract

BACKGROUND: Previous studies showed that an intravenous infusion of donor blood cells facilitates tolerance to ACI heart allografts in Lewis rat hosts given posttransplant total lymphoid irradiation (TLI) and anti-thymocyte globulin (ATG). The object of the current study was to compare tolerance induction using donor cells that do or do not induce chimerism.
METHODS: Normal peripheral blood mononuclear cells (PBMC), granulocyte colony-stimulating factor (G-CSF)-mobilized PBMC, and bone marrow (BM) cells from ACI donors were tested for their capacity to prolong ACI heart allograft survival in Lewis hosts. Chimerism, anti-donor cell reactivity, and cytokine gene expression in grafts were determined.
RESULTS: Intravenous injections of equal numbers of all three donor cells markedly prolonged graft survival (median: >164 to >175 days) as compared to uninjected controls (median: 53 days). Chimerism among T and B cells in the blood was determined by immunofluorescent staining in hosts bearing long-term (> 150 days) grafts. Although no chimerism was detected in hosts given normal or G-CSF-mobilized PBMC, chimerism was detected at variable levels in all hosts given BM cells. Vigorous anti-donor reactivity in the mixed leukocyte reaction was present only in non-chimeric hosts. Long-term grafts from hosts given normal ACI PBMC developed chronic rejection, but those from hosts given ACI BM cells did not. The latter hosts showed the lowest levels of intragraft cytokine mRNA.
CONCLUSIONS: Chimeric tolerance is more robust than non-chimeric tolerance in the model of posttransplant TLI, ATG, and donor cell infusion, and is associated with less chronic rejection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10532547     DOI: 10.1097/00007890-199910150-00023

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  8 in total

Review 1.  Path to clinical transplantation tolerance and prevention of graft-versus-host disease.

Authors:  Samuel Strober
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

2.  Requirement for interactions of natural killer T cells and myeloid-derived suppressor cells for transplantation tolerance.

Authors:  D Hongo; X Tang; J Baker; E G Engleman; S Strober
Journal:  Am J Transplant       Date:  2014-10-13       Impact factor: 8.086

Review 3.  Translational studies in hematopoietic cell transplantation: treatment of hematologic malignancies as a stepping stone to tolerance induction.

Authors:  Samuel Strober; Thomas R Spitzer; Robert Lowsky; Megan Sykes
Journal:  Semin Immunol       Date:  2011-06-25       Impact factor: 11.130

Review 4.  Preclinical and clinical studies on the induction of renal allograft tolerance through transient mixed chimerism.

Authors:  Tatsuo Kawai; A Benedict Cosimi; David H Sachs
Journal:  Curr Opin Organ Transplant       Date:  2011-08       Impact factor: 2.640

Review 5.  Stable mixed chimerism and tolerance to human organ transplants.

Authors:  Samuel Strober
Journal:  Chimerism       Date:  2016-02-08

6.  The changed balance of regulatory and naive T cells promotes tolerance after TLI and anti-T-cell antibody conditioning.

Authors:  R G Nador; D Hongo; J Baker; Z Yao; S Strober
Journal:  Am J Transplant       Date:  2009-12-23       Impact factor: 8.086

7.  Induced tolerance to rat liver allografts involves the apoptosis of intragraft T cells and the generation of CD4(+)CD25(+)FoxP3(+) T regulatory cells.

Authors:  Masato Fujiki; Carlos O Esquivel; Olivia M Martinez; Samuel Strober; Shinji Uemoto; Sheri M Krams
Journal:  Liver Transpl       Date:  2010-02       Impact factor: 5.799

Review 8.  Establishment of Chimerism and Organ Transplant Tolerance in Laboratory Animals: Safety and Efficacy of Adaptation to Humans.

Authors:  Robert Lowsky; Samuel Strober
Journal:  Front Immunol       Date:  2022-02-10       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.